Immatics NV, also known as Immatics Biotechnologies, is a renowned biopharmaceutical company and a pioneer in the development of T-cell receptor (TCR) therapies that are specifically designed to treat cancer. The company’s ticker symbol is IMTX and it is publicly traded on the Nasdaq market. Immatics NV was founded in 2000 and has its headquarters in Tuebingen, Germany, with additional operations in Houston, TX, and Munich.
The company focuses on immunotherapies that use the body's immune system to fight cancer, specializing on three technologically advanced and complementary platforms: Adoptive Cell Therapies, TCR Bispecifics, and TCR targets.
Immatics NV's TCR-T cell therapy specifically converts the patient's own T cells into cancer-specific effectors, taking advantage of the patient's functional immunity. The Adoptive Cell Therapy is aimed at selecting the best T cell receptor-based immune response for targeting specific types of cancer.
On the other hand, Immatics' TCR Bispecifics are part of an off-the-shelf approach constituting a unique plug-and-play T-cell redirecting strategy designed to harness the body's immune system to kill off cancer cells. It targets tumor-associated peptides which are minimally invasive to normal tissues and thus reduce the risk of side effects.
In addition, Immatics NV focuses on discovering novel targets for CAR-T and TCR therapies. The company works on developing a comprehensive and proprietary library of TCR Therapeutics targeting intracellular as well as surface cancer antigens referred as XPRESIDENT.
The company has partnered with several high-profile organizations, such as Amgen, Genmab, BioNTech, and the University of Texas MD Anderson Cancer Center. These collaborations have helped Immatics on its mission to deliver the power of T-cells and to unlock new avenues for cancer therapy.
Over its existence, the company has established a strong scientific and clinical track record, disrupting cancer treatment with aims to cure cancers that are currently untreatable. The company’s commitment to its vision has led to a number of advancements in the world of T-cell receptor technology and immunotherapy.
Immatics NV projects an innovative, pioneering attitude within the biotechnology industry, fully committed to transforming the prognosis for cancer patients by advancing the clinical development of personalized immunotherapies. Their vision is to revolutionize the treatment of cancer and to ensure a future where cancer is no longer a deadly disease.